Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver

Drug Metabolism and Disposition

Volumn 27, Issue 2, 1999, Pages 173-179

  Jacobsen, Wolfgang ^a   Kirchner, Gabriele ^b   Hallensleben, Katrin ^b   Mancinelli, Laviero ^a   Deters, Michael ^c   Hackbarth, Ingelore ^b   Benet, Leslie Z ^a   Sewing, Karl Fr ^b   Christians, Uwe ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; MEVINOLIN; PRAVASTATIN; TROLEANDOMYCIN;

ARTICLE; CATALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MICHAELIS CONSTANT; PRIORITY JOURNAL; RISK FACTOR;

BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; KINETICS; LOVASTATIN; MALE; MICROSOMES, LIVER; PRAVASTATIN;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0032911163     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Anderson KM, Castelli WP and Levy D (1987) Cholesterol and mortality: 30 years follow up from the Framingham Study. J Am Med Assoc 257:2176-2180.
2. Ashforth EIL, Carlile DJ, Chenery R and Houston JB (1995) Prediction of in vivo disposition from in vitro systems: Clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. J Phamacol Exp Ther 274:761-766.
3. Bradford RH, Shear CL and Chremos AN (1991) Clinical evaluation of lovastatin (EXCEL) study results. Arch Intern Med 151:43-49.
4. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S and Kannel WB (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. J Am Med Assoc 256:2835-2838.
5. Christians U, Zimmer KO, Wonigeit K, Maurer G and Sewing KF (1988) Liquid chromatographic measurement of cyclosporin A and its metabolites in blood, bile and urine. Clin Chem 34:34-39.
6. Dietschy JM and Wilson JD (1970) Regulation of cholesterol metabolism 1-3. N Engl J Med 282:1128-1138, 1179-1183, and 1241-1249.
7. Estabrook RW and Werringloer J (1978) The measurement of difference spectra: Application to the cytochromes of microsomes. Methods Enzymol 52:212-220.
8. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY and Weinstein SH (1991) Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 19:740-748.
9. Gordon T, Castelli WP, Hjortland MC, Kannel WB and Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med 62:707-714.
10. Gordon T, Kannel WB, Castelli WP and Dawber TR (1981) Lipoprotein, cardiovascular disease, and death: The Framingham Study. Arch Intern Med 141:1128-1131.
11. Guengerich FP (1982) Microsomal enzymes involved in toxicology: Analysis and separation, in Principles and Methods of Toxicology (Hayes AW ed) pp 609-637, Raven Press, New York.
12. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano PR ed), 2nd ed., pp 473-535, Plenum Press, New York.
13. Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB and Duggan DE (1993) Biotransformation of lovastatin: V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metab Dispos 21:1003-1011.
14. Henwood JM and Heel RC (1988) Lovastatin: A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 36:429-454.
15. Houston JB and Carlile DJ (1997) Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29:891-922.
16. Hsu I, Spinler SA and Johnson NE (1995) Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 29:743-759.
17. Iwatsubo T, Hirota N, Ooie T, Suzuki H and Sugiyama Y (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17:273-310.
18. Kitazawa E, Tamura N, Iwabuchi H, Uchiyama M, Muramatsu S, Tkahagi H and Tanaka M (1993) Biotransformation of pravastatin sodium (I): Mechanism of enzymatic transformation of epimerization of an allylic hydroxy group of pravastatin sodium. Biochem Biophys Res Commun 192:597-602.
19. Lennernäs H and Fager G (1997) Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences. Clin Pharmacokinet 32:403-425.
20. Muramatsu S, Miyaguchi K, Iwabuchi H, Matsushita Y, Nakamura T, Kinoshita T, Tanaka M and Takahagi H (1992) Metabolism of pravastatin sodium in isolated rat hepatocytes. Xenobiotica 22:487-498.
21. Neuvonen PJ and Jalava MD (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60:54-61.
22. Neuvonen PJ, Kantola T and Krivistö KT (1998) Simvastatin, but not pravastatin, is very susceptible to interact with the CYP3A inhibitor itraconazole. Clin Pharmacol Ther 63:332-341.
23. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes: I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
24. Quion JAV and Jones PH (1994) Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 27:94-103.
25. Rendic S and DiCarlo FJ (1997) Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580.
26. Singhvi SM, Pan HY, Morrison RA and Willard DA (1990) Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br Clin Pharmacol 29:239-243.
27. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
28. Soucek P and Gut I (1992) Cytochrome P-450 in rats: Structures, functions, properties and relevant human forms. Xenobiotica 22:83-103.
29. Tobert JA (1988) Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 318:48.
30. Transon C, Leemann T and Dayer P (1996) In vitro comparative inhibition profiles of major human drug metabolising P450 isozymes (CYP2C9. CYP2D6, and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 50:209-215.
31. Triscari J, O'Donnell D, Zinny M and Pan HY (1995) Gastrointestinal absorption of pravastatin in healthy subjects. J Clin Pharmacol 35:142-144.
32. Vyas KP, Kari PH, Pitzenberger SM, Halpin RA, Ramjit HG and Arison B (1990) Biotransformation of lovastatin: I. Structure elucidation of in vitro and in vivo metabolites in rat and mouse. Drug Metab Dispos 18:203-211.
33. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP and Vyas KP (1991) Biotransformation of lovastatin: IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 299:355-361.